Comparative Pharmacology
Head-to-head clinical analysis: MEPROSPAN versus MILTOWN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROSPAN versus MILTOWN.
MEPROSPAN vs MILTOWN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
Miltown (meprobamate) is a carbamate derivative that acts as a central nervous system depressant. Its mechanism of action is not fully understood, but it is believed to exert its effects by modulating GABAergic neurotransmission, possibly by binding to GABA receptors and enhancing inhibitory neurotransmission. It also has sedative, anxiolytic, and muscle relaxant properties.
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
400 mg orally 3-4 times daily; maximum 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
10 hours (range 6-17 hours); prolonged in hepatic or renal impairment.
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Primarily renal, with 10-20% excreted unchanged; remainder as inactive metabolites (e.g., hydroxymeprobamate). Less than 2% fecal.
Category C
Category C
Anxiolytic
Anxiolytic